Beijing Nuohe Zhiyuan Technology Co., Ltd. is a high-tech enterprise focusing on the application of cutting-edge molecular biology technology and high-performance computing in the field of life science research and human health, and is engaged in tumor gene testing, genetic testing and other businesses
Founded in March 2011 in Beijing Zhongguancun Life Science Park, Beijing Novo Zhiyuan Technology Co., Ltd. focuses on pioneering cutting-edge molecular biology technologies and the application of high-performance computing in the field of life science research and human health, and is committed to becoming the world's leading provider of genomics products and services. Headquartered in Beijing, the company has laboratories or experimental bases in Tianjin, Nanjing, the United States and Singapore, and subsidiaries in Hong Kong, the United States and the United Kingdom, with an office area of more than 26'000m2.
At present, Novo Zhiyuan has become the world's largest sequencing service center, which can complete the ultra-high throughput of 200'000 people per year for whole genome sequencing. The sequencing platforms introduced by Novo include 10 PacBio Sequel, 25 HiSeq X, 10 HiSeq 2000/2500, 4 MiSeq, 1 HiSeq 4000, 4 NextSeq 500, and 6 Life Ion Proton (DA8600); The world's leading high-performance computing platform and data center computing capacity has reached 878T flops, with a total memory of 368TB and a total storage of 26.8PB, effectively supporting the demand for big data analysis and storage in the two major fields of life science research and healthcare.
At present, Novo Zhiyuan has established a high-quality comprehensive team from top universities at home and abroad, multidisciplinary and interdisprocal, of which nearly 68% have master's degree or above. The bioinformatics professional analysis team led by the founder, Dr. Li Ruiqiang, is guided by technical product development and has accumulated rich experience in molecular pathology, tumor diagnosis and treatment, genetic disease detection and big data integration.
Novozhiyuan's business covers scientific and technological services, tumor genetic testing and genetic testing, and provides gene sequencing and bioinformation technology support services for global research universities, scientific research institutes, hospitals, pharmaceutical research and development enterprises, agricultural enterprises, etc. Relying on a complete molecular pathology testing platform, tumor testing provides accurate molecular pathology detection products and services for solid tumors for patients, hospitals and pharmaceutical companies, with deep gene sequencing and big data analysis and interpretation as the core, continues to develop world-leading tumor genetic testing products, and provides tumor precision treatment solutions such as tumor medication guidance, dynamic monitoring, and tumor genetic susceptibility gene detection. In terms of genetic testing, Novo Zhiyuan has developed a series of testing services based on next-generation sequencing technology, including pre-pregnancy genetic testing, neonatal genetic screening, personal genome and other products, and is committed to developing the application of genomics in the field of human health, focusing on reproductive health and personal genomics, and providing customers with professional genetic consulting services.
